Life Sciences company Newtricious has secured the backing of a consortium of investors who will help it to continue to develop its first products focusing on the maintenance of health in people at risk for chronic diseases such as macular degeneration and cardiovascular illnesses.
Jos Nelissen, founder and CEO of Newtricious, is delighted with this investment: "With these investment funds we get strategic partners in our company who fully support our vision and strategy, and who will help us to further develop these. It gives us the financial room and the possibilities to accelerate the realization of our innovative development strategy, and to bring our products to the market in collaboration with commercial partners - in order to make them rapidly available for consumers worldwide."
Jan van der Hoeven, founder and CEO of Brabant Life Sciences Seed Fund (BLSF), one of the investors, said: "We are pleased with this investment which fits perfectly in the strategy of our Fund. Newtricious is a company that shows in its strategy how one can develop true added value in the agro-food industry. It is a company that undertakes the development of functional foods in an energetic and responsible manner. The company has the management team that has the right expertise to do the right things on the interface between food and pharma."
Ozempic effective for patients with chronic kidney damage